Plain-English translation of NCT05470491 on ClinicalTrials.gov ↗ ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a bone marrow transplant approach for people living with HIV who have been diagnosed with blood cancer. The transplant uses bone marrow from a family member who is a partial genetic match, followed by treatment with three medications—cyclophosphamide, bortezomib, and —designed to prevent the transplanted cells from attacking your body and to help protect the new cells from HIV infection.
For many years, people living with HIV were not considered good candidates for bone marrow transplants because of concerns about infections, drug interactions, and finding a suitable donor. This trial exists to test whether modern HIV medications and new transplant techniques can make this life-saving treatment safe and accessible for people with HIV who have blood cancer.
You likely qualify if…
You likely don't qualify if…
You would receive conditioning chemotherapy to prepare your bone marrow for the transplant, followed by the bone marrow transplant itself from your family donor. After the transplant, you would receive the three preventive medications over several months. You would have frequent clinic visits and blood tests in the first months, gradually spacing out over time as you recover. The trial is designed to monitor both your recovery and how well the new bone marrow cells work while protecting you from rejection and HIV infection.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States